St. Jude Medical Earnings Preview
Watch St. Jude Medical's (NYS: STJ) earnings report to see if it can beat analyst expectations for the fifth consecutive quarter. The company will unveil its latest earnings Wednesday. St. Jude Medical develops, manufactures, and distributes cardiovascular medical devices.
What analysts say:
- Buy, sell, or hold?: Analysts are bullish on this stock with 21 analysts rating it as a buy and only one rating it as a sell. Analysts like St. Jude Medical better than competitor Boston Scientific overall. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared with three months ago.
- Revenue Forecasts: On average, analysts predict $1.37 billion in revenue this quarter. That would represent a rise of 10.5% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is earnings of $0.76 per share. Estimates range from $0.74 to $0.79.
What our community says:
CAPS All-Stars are solidly backing the stock with 96.6% awarding it an "outperform" rating. The community at large agrees with the All-Stars with 95.2% granting it a rating of "outperform." Fools are keen on St. Jude Medical and haven't been shy with their opinions lately, logging 129 posts in the past 30 days. Even with a robust four out of five stars, St. Jude Medical's CAPS rating falls a little short of the community's upbeat outlook.
St. Jude Medical's profit has risen year over year by an average of 6.6% over the past five quarters. Revenue has now gone up for three straight quarters.
For all our St. Jude Medical-specific analysis, including earnings and beyond, add St. Jude Medical to My Watchlist.
The Motley Fool owns shares of St. Jude Medical.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
At the time this article was published
Copyright © 1995 - 2011 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.